Pacira Pharmaceuticals Stock Shares Owned By Institutions
| PCRX Stock | USD 26.51 0.01 0.04% |
Pacira Pharmaceuticals fundamentals help investors to digest information that contributes to Pacira Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Pacira Stock. The fundamental analysis module provides a way to measure Pacira Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacira Pharmaceuticals stock.
Pacira |
Pacira Pharmaceuticals Company Shares Owned By Institutions Analysis
Pacira Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Pacira Pharmaceuticals Shares Owned By Institutions | 98.74 % |
Most of Pacira Pharmaceuticals' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 98% of Pacira Pharmaceuticals are shares owned by institutions. This is 121.19% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 151.82% lower than that of the firm.
Pacira Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira Pharmaceuticals' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pacira Pharmaceuticals by comparing valuation metrics of similar companies.Pacira Pharmaceuticals is currently under evaluation in shares owned by institutions category among related companies.
Pacira Fundamentals
| Return On Equity | 0.051 | ||||
| Return On Asset | 0.0335 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 1.54 B | ||||
| Shares Outstanding | 46.52 M | ||||
| Shares Owned By Insiders | 1.26 % | ||||
| Shares Owned By Institutions | 98.74 % | ||||
| Number Of Shares Shorted | 3.45 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 1.85 X | ||||
| Revenue | 674.98 M | ||||
| Gross Profit | 393.23 M | ||||
| EBITDA | 162.9 M | ||||
| Net Income | 41.95 M | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 586.04 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 18.72 X | ||||
| Cash Flow From Operations | 154.65 M | ||||
| Short Ratio | 7.57 X | ||||
| Earnings Per Share | 0.87 X | ||||
| Price To Earnings To Growth | (3.83) X | ||||
| Target Price | 46.4 | ||||
| Number Of Employees | 711 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 1.27 B | ||||
| Total Asset | 1.57 B | ||||
| Retained Earnings | (106.8 M) | ||||
| Working Capital | 412.61 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
| Net Asset | 1.57 B |
About Pacira Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacira Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pacira Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pacira Pharmaceuticals' short interest history, or implied volatility extrapolated from Pacira Pharmaceuticals options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pacira Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Pacira Pharmaceuticals Piotroski F Score and Pacira Pharmaceuticals Altman Z Score analysis. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.